Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 4,355

Document Document Title
WO/2022/166990A1
Provided in the present invention are a 2-(substituted phenoxy)aromatic formic acid FTO inhibitor, a preparation method therefor and the use thereof, and specifically disclosed are a compound represented by formula (I), and the use of a ...  
WO/2022/164857A1
Disclosed are compounds of Formula 1, including all geometric and stereoisomers, N -oxides, and salts thereof, Wherein R1, R2, R3, A, X and Q are as defined in the disclosure. Also disclosed are compositions containing the compounds of F...  
WO/2022/155171A1
Formation of methanoic acid, during the production of Hexahydro-1,3,5-trinitro-1,3,5- triazine and Octahydro-1,3,5,7-tetranitro-1,3,5,7-tetrazocine via the legacy Bachmann nitrolysis process, is avoided when the workup is performed under...  
WO/2022/038365A9
The invention relates to compounds of formula (I) and to their use in treating or preventing an inflammatory disease or a disease associated with an undesirable immune response: wherein R, R1, R2 and RB are as defined herein.  
WO/2022/142534A1
Disclosed in the present invention are a tetrazine compound, a preparation method therefor, and an application thereof. The tetrazine compound provided by the present invention can be used for implementing selective tetrazine labeling of...  
WO/2022/133537A1
This disclosure relates to compounds that include a first chelating ligand selective for 89Zr linked by a linker group to a second chelating ligand selective for a radionuclide other than 89Zr. Also disclosed are complexes, pharmaceutica...  
WO/2022/138703A1
Provided is a gas-generating agent that generates a gas through the radiation of light. The gas-generating agent comprises: a gas-generating moiety having a specific structure; and a fluorinated aliphatic hydrocarbon group, which may con...  
WO/2022/129724A1
The present invention relates to a sequential one-pot synthesis of TKX-50, suitable for larger-scale production, during which an acetyl halide is used during the cyclization of diazidoglyoxime so as to obtain 1,1'-diacetyl-5,5'-bistetraz...  
WO/2022/132924A1
The present invention provides novel compounds: (I), and (II) methods of making such compounds, methods of using such compounds for pretargeted imaging, and preparations of formulations for such use.  
WO/2022/126275A1
The present invention relates to radiolabelled compounds for in vivo imaging or treatment of diseases or conditions characterized by expression of prostate-specific membrane antigen.  
WO/2022/129125A1
The present invention related to compounds of Formula (I):(I) or an agronomically acceptable salt thereof, wherein R1, R2, R3, R4 and R5 are as described herein. The invention further relates to compositions comprising said compounds, to...  
WO/2022/129508A1
The present invention concerns a family of organometallic compounds of formula (I) and its use to obtain contrast media applicable in various diagnostic imaging techniques such as X-ray, MRI, PET or SPECT or combinations of these techniq...  
WO/2022/122035A1
Provided are a coagulation factor XIa inhibitor, a preparation method, a pharmaceutical composition and the use thereof for preventing or treating diseases related to the activity of FXIa. Specifically, provided are an amide derivative a...  
WO/2022/120353A1
The present invention provides compounds, compositions thereof, and methods of using the same.  
WO/2022/117619A1
The invention relates to a process for preparing Gadoteridol of formula (I).In particular, the process comprises the use of propylene oxide in the alkylation step of the compound of formula (II), wherein propylene oxide is directly react...  
WO/2022/117877A1
The present invention provides cyclic tetrapeptides consisting of alternating α- and β-amino acids and metal complexes thereof. The cyclic tetrapeptides are particularly useful for coordinating a metal selected from Pb, Cd, Hg and As. ...  
WO/2022/111605A1
The present disclosure relates to an aryl or heteroaryl substituted 5-membered aromatic heterocyclic compound and the use thereof. In particular, provided is a compound as shown in formula I or a pharmaceutically acceptable salt thereof,...  
WO/2022/106669A1
The invention relates in particular to a process for the preparation of a compound of formula (I) wherein R1 and R2 are as defined in the description and in the claims.  
WO/2022/106633A1
The present disclosure relates to the synthesis of prostate specific membrane antigen (PSMA) ligands that are useful in the treatment of diseases like cancer. In particular, the disclosure relates to a method for synthesizing PSMA ligand...  
WO/2022/106629A1
The present disclosure relates to the synthesis of prostate specific membrane antigen (PSMA) ligands that are useful in the treatment of diseases like cancer. In particular, the disclosure relates to a method for synthesizing PSMA ligand...  
WO/2022/100696A1
Disclosed in the present application are a multi-specific bioconjugate linker and a synthetic method therefor, and specifically, a compound or a tautomer, a mesomer, a racemate, an enantiomer, or a diastereoisomer thereof, or a mixture t...  
WO/2022/103827A1
Disclosed herein are methods of treating a cancer that overexpresses NQOl comprising administering KP372-1. In some embodiments, KP372-1 is administered with a polymerase inhibitor.  
WO/2022/095965A1
Disclosed in the present invention is a tetrazole derivative having a structure represented by a general formula I. Also disclosed in the present invention are a composition containing the tetrazole derivative and an application of the t...  
WO/2022/085570A1
The present invention pertains to a method that is for producing a radioactive zirconium labelled complex and that can achieve a high labelling rate in a reaction between a ligand compound and radioactive zirconium ions. The production m...  
WO/2022/085571A1
A method for producing a radioactive zirconium complex according to the present invention comprises a step for reacting a radioactive zirconium ion, a ligand compound comprising DOTA or a DOTA derivative and an additive such as hydroxybe...  
WO/2022/076563A1
The instant invention describes macrocyclic compounds having antiproliferation activity, and methods of treating disorders such as cancer, tumors and cell proliferation related disorders.  
WO/2022/074673A1
A tetra-aza corand compound of formula (Ia) and compound of formula (Ib) and salts thereof. The tetra-aza corand of formula (Ia) and (Ib) of the present invention relates to novel corand entity having a substantially enclosed volume and ...  
WO/2022/072374A1
Disclosed herein, inter alia, is a light-controlled bioorthogonal tetrazine ligation.  
WO/2022/067082A1
The present invention provides a fused heteroaryl compound having a CaMKII inhibitory action, which is expected to be useful as an agent for the prophylaxis or treatment of cardiac diseases (particularly catecholaminergic polymorphic ven...  
WO/2022/061193A1
Provided are vitamin D3 derivatives of formula (I), pharmaceutical compositions thereof, and pharmaceutical or medical uses thereof for treating metabolic disease, a liver disease, obesity, diabetes, cardiovascular disease, or cancer in ...  
WO/2022/058733A1
The present invention relates to compounds for stabilising the native tetrameric form of transthyretin and protecting it from proteolytic cleavage; compounds for use in the prevention and treatment of transthyretin amyloidosis; and agent...  
WO/2022/023240A1
The invention relates to a process for the preparation of dimeric contrast agents for use in Magnetic resonance Imaging (MRI), in particular [μ-[1-[bis[2-(hydroxy-kO)-3- [4,7,10-tris[(carboxy-kO)methyl]-1,4,7,10-tetraazacyclododec -1-yl...  
WO/2022/016345A1
Disclosed is an application of a composition for preventing and/or eliminating platelet aggregation in an in vitro blood sample. The composition comprises at least one compound selected from the group consisting of formula (I) and a salt...  
WO/2022/005998A1
The present disclosure provides compositions and methods for the detection and treatment of cancer. Specifically, the compositions of the present technology include novel compounds that may be complexed with a radioisotope. Also disclose...  
WO/2021/250163A1
The present invention refers to a process for obtaining gadoterate meglumine from high purity tetraxetan (DOTA) which does not require the use of organic solvents and optimizes the conditions of the synthetic process. The tetraxetan from...  
WO/2021/251551A1
The present invention relates to a compound of formula 1 and a pharmaceutical composition containing same. This compound may be useful as: a therapeutic agent for degenerative brain diseases including dementia or cranial nerve diseases a...  
WO/2021/252640A1
The present disclosure relates to compounds of formulas (A) and (I), pharmaceutically acceptable salts thereof, and solvates of any of the foregoing, pharmaceutical compositions comprising the same, methods of preparing the same, interme...  
WO/2021/247634A1
Provided herein are compounds of Formula (I''), Formula (I'), Formula (I), Formula (II'), and Formula (II), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labele...  
WO/2021/228992A1
The present invention relates to novel tetrazine compounds for use in pretargeted in vivo imaging and in therapy and to the precursors of the tetrazine compounds. The compounds are suitable for use in click chemistry, i.e. reactions that...  
WO/2021/209383A1
The present invention related to compounds of Formula (I) or an agronomically acceptable salt thereof, wherein Q, R2, R3, R4 and R5 are as described herein. The invention further relates to compositions comprising said compounds, to meth...  
WO/2021/204666A1
The invention relates to isophthalic acid diamides having general formula (I) as herbicides. In this formula (I), X and Y represent radicals such as hydrogen, alkyl and halogen. Z1 and Z2 represent radicals such as alkyl, cycloalkyl and ...  
WO/2021/204669A1
The invention relates to substituted isophthalic acid diamides and to their use as herbicides. Disclosed are isophthalic acid diamides having general formula (I) as herbicides. In this formula (I), Z1 and Z2 represent radicals such as al...  
WO/2021/204667A1
The invention relates to substituted isophthalic acid diamides and to their use as herbicides. Disclosed are isophthalic acid diamides having general formula (I) as herbicides. In this formula (I), Z1 and Z2 represent radicals such as al...  
WO/2021/204665A1
The invention relates to isophthalic acid diamides having general formula (I) as herbicides. In this formula (I), X, Y and Z represent radicals such as hydrogen, alkyl and halogen. Q represents a heterocyclic ring such as tetrazolyl.  
WO/2021/202914A1
A method for purifying lutetium includes providing a solid composition comprising ytterbium and lutetium and subliming or distilling ytterbium from the solid composition at a temperature of about 1196°C to about 3000°C to leave a lutet...  
WO/2021/193410A1
A compound represented by formula (I) or a salt thereof, and an herbicide containing as an active ingredient at least one selected from the group consisting of said compound and salts thereof. (In formula (I), Ra and Rb each independentl...  
WO/2021/180611A1
A method of making copper (I) 5-nitrotetrazolate (DBX-1) in isolated form comprising: a) reacting bis(ethylenediamine) copper (II) nitrotetrazolate with nitric acid or sulfuric acid to form a reaction product, subsequently b) reducing th...  
WO/2021/180655A1
The present invention provides novel hydroquinone derivatives of formula (I), processes of preparation, as well as pharmaceutical compositions and methods of treating and/or preventing e.g. autoimmune, immunological, rheumatology, vascul...  
WO/2021/175147A1
A prostate-specific membrane antigen (PSMA)-binding ligand conjugate and an application thereof. Specifically, a conjugate as shown in formula I: Y1-L1-Z1 (I), wherein Y1 is a chelate moiety, Z1 is a PSMA-binding ligand moiety, and L1 is...  
WO/2021/162054A1
The purpose of the present invention is to provide a type 2 ryanodine receptor (RyR2) activity inhibitor having an excellent effect of inhibiting RyR2 activity. An RyR2 activity inhibitor comprising a compound represented by formula (...  

Matches 1 - 50 out of 4,355